Automated insulin delivery (AID) systems with hybrid closed-loop (HCL) or advanced hybrid closed-loop (AHCL) algorithms modulate insulin delivery based on real-time CGM and a system-specific SG range or target to minimize hypoglycemia and improve %TIR.10 Several 6-month randomized controlled trials (RCTs) have demonstrated safe and clinically significant improvement in A1C,11–14 %TIR,11–15 and %TBR <70 mg/dL11–15 with different AID therapies; all of which comprised either adjunctive or non-adjunctive CGM technology components. The gene discussed is INS; the disease is Hypoglycemia.